


Peter J. Krause  
Paula B. Kavathas  
Nancy H. Ruddle  
*Editors*

# Immunoepidemiology



---

## Immunoepidemiology

---

Peter J. Krause  
Paula B. Kavathas  
Nancy H. Ruddle  
Editors

# Immunoepidemiology



*Editors*

Peter J. Krause

Department of Epidemiology of Microbial Diseases

Yale School of Public Health and Departments of Medicine and Pediatrics

Yale School of Medicine

New Haven, CT, USA

Paula B. Kavathas

Departments of Laboratory Medicine and Immunobiology

Yale School of Medicine

New Haven, CT, USA

Nancy H. Ruddle

Department of Epidemiology of Microbial Diseases

Yale School of Public Health

New Haven, CT, USA

ISBN 978-3-030-25552-7

ISBN 978-3-030-25553-4 (eBook)

<https://doi.org/10.1007/978-3-030-25553-4>

© Springer Nature Switzerland AG 2019

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Cover design: © Krause, Kavathas, and Ruddle 2020

This Springer imprint is published by the registered company Springer Nature Switzerland AG  
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

*We dedicate this book to our families and students*

---

## Preface

This textbook focuses on the nascent field of immunoepidemiology that addresses how differences in immune responses among individuals affect the epidemiology of infectious diseases, cancer, hypersensitivity, and autoimmunity. The idea for the book originated from a course entitled “Immunology for Epidemiologists” at the Yale School of Public Health that was required for MPH students in the Epidemiology of Microbial Diseases Department. While many fine textbooks are available that address the immunological responses of *individuals* to pathogens, these provided very little information regarding how immunological variation among *populations* affects the epidemiology of disease. And yet, it has long been recognized that there is great immunologic diversity among people, which can have a profound effect on the epidemiology of disease. Careful review of the immunologic and epidemiologic literature revealed that there have been relatively few publications concerning immunoepidemiology and that no textbook is available on the subject. This textbook, therefore, aims to fill this void by providing a much-needed tool to comprehensively and efficiently teach immunoepidemiology.

The emphasis of the book, as in the course that inspired it, is on infectious diseases, autoimmunity, and cancer. We recognize that many of the same immune principles can be applied to chronic diseases that are not covered here. The roles of acute and chronic inflammation are becoming ever more recognized in cardiovascular, metabolic, and neurologic diseases.

The book includes a section on the basic principles of immunology and then applies them to particular examples of disease in human populations. The primary target audience for this textbook is Masters of Public Health students. Others who should also find it of interest include PhD students in epidemiology and immunology, medical students, generalists, and specialists in immunology, infectious diseases, cancer, and rheumatology.

New Haven, CT, USA

Peter J. Krause  
Paula B. Kavathas  
Nancy H. Ruddle

---

## Acknowledgments

We thank the following individuals for their excellent illustrations: Yixin Yang (major illustrator), Trisha P. Gupte, Jennifer Yoon, Francesica Tizard, and Wendolyn Hill. We thank Francesica Tizard for her administrative help. We thank our Yale colleagues for their continual scientific input, particularly Najla Arshad, João Pereria, Peter Cresswell, Marie Landry, Michel Ledizet and Kenneth Kidd. We thank the Gordon and Llura Gund Foundation for their support (PJK).

---

# Contents

## Section I INTRODUCTION

<b>1</b>	<b>Introduction to Immunology, Epidemiology, and Immunoepidemiology . . . . .</b>	<b>3</b>
	Linda M. Niccolai, Nancy H. Ruddle, and Peter J. Krause	
1.1	Introduction . . . . .	3
1.2	Immunology . . . . .	3
1.2.1	Definition . . . . .	3
1.2.2	History . . . . .	4
1.2.3	Major Concepts . . . . .	7
1.3	Epidemiology . . . . .	8
1.3.1	Definition . . . . .	8
1.3.2	History: Three Eras . . . . .	8
1.3.3	Major Concepts . . . . .	10
1.4	Immunoepidemiology . . . . .	12
1.4.1	Definition . . . . .	12
1.4.2	History . . . . .	12
1.4.3	Major Concepts . . . . .	13
1.4.4	Immunoepidemiologic Study Objectives and Tools . . . . .	14
	References . . . . .	16

## Section II IMMUNOLOGY BASICS

<b>2</b>	<b>Organization and Cells of the Immune System . . . . .</b>	<b>21</b>
	Paula B. Kavathas, Peter J. Krause, and Nancy H. Ruddle	
2.1	Introduction . . . . .	21
2.1.1	Surface Barriers and Mucosal Immunity . . . . .	21
2.2	Cells of the Immune System . . . . .	22
2.2.1	Overview . . . . .	22
2.2.2	Cells of the Innate Immune System . . . . .	23
2.2.3	Cells of the Adaptive Immune System . . . . .	27
2.3	Hematopoiesis . . . . .	27
2.4	Cytokines: Communication Signals Between Cells . . . . .	29
2.4.1	Definition . . . . .	29
2.5	Chemokines: Directional Signals . . . . .	29
2.6	The Lymphatic System and Lymphoid Organs . . . . .	31

2.6.1	Definition . . . . .	31
2.6.2	Lymphatic System Pathology . . . . .	33
2.6.3	Primary Lymphoid Organs . . . . .	33
2.6.4	Secondary Lymphoid Organs . . . . .	33
2.6.5	Tertiary Lymphoid Tissues . . . . .	36
	References . . . . .	37
<b>3</b>	<b>Innate Immunity: Recognition and Effector Functions . . . . .</b>	<b>39</b>
	Paula B. Kavathas, Peter J. Krause, and Nancy H. Ruddle	
3.1	Introduction . . . . .	39
3.2	Pattern Recognition Receptors . . . . .	40
3.3	Principles of Receptors and Signal Transduction . . . . .	43
3.4	Responses Elicited by Pattern Recognition Receptors . . . . .	45
3.4.1	Inflammation . . . . .	45
3.4.2	Antimicrobial Responses . . . . .	48
3.5	Natural Killer (NK) Cell Recognition and Response . . . . .	48
3.6	The Complement System . . . . .	50
3.6.1	Definition . . . . .	50
3.7	Mechanisms of Cell Death . . . . .	52
	References . . . . .	53
<b>4</b>	<b>Adaptive Immunity: Antigen Recognition by T and B Lymphocytes . . . . .</b>	<b>55</b>
	Paula B. Kavathas, Peter J. Krause, and Nancy H. Ruddle	
4.1	Introduction . . . . .	55
4.2	Cells of the Adaptive Immune System . . . . .	56
4.2.1	T Cells . . . . .	56
4.2.2	B Cells . . . . .	56
4.3	B Cell Receptors (BCRs), Antibody, and T Cell Receptors (TCRs) . . . . .	58
4.3.1	Structure of B Cell Receptor and Antibody . . . . .	58
4.3.2	Structure of the T Cell Receptor . . . . .	58
4.4	The Major Histocompatibility Complex (MHC): Antigen Processing and Presentation . . . . .	58
4.4.1	Definition . . . . .	58
4.4.2	MHC Class I and MHC Class II Proteins . . . . .	61
4.4.3	Antigen Processing and Presentation . . . . .	61
4.5	T Cell Co-receptors CD4 and CD8 . . . . .	63
4.6	Generation of B and T Cell Receptors . . . . .	64
4.6.1	Introduction . . . . .	64
4.6.2	Generating a B Cell Receptor: V(D)J Recombination and Combinatorial Diversity . . . . .	65
4.6.3	Mechanisms Generating B Cell Receptor Diversity . . . . .	66
4.6.4	Generation of T Cell Receptors . . . . .	67
4.7	Structural Variation in Immunoglobulin Constant Regions . . . . .	68
4.8	T Cell Subsets with Relatively Conserved T Cell Receptors . . . . .	69
4.8.1	Invariant NK T Cells (iNKT) . . . . .	69
4.8.2	Gamma Delta T Cells (TCR $\gamma\delta$ T Cells) . . . . .	69
4.9	T and B Cell Development and Central Tolerance . . . . .	70

---

4.9.1	Introduction . . . . .	70
4.9.2	Education of T Cells in the Thymus, Positive and Negative Selection, and Central Tolerance . . . . .	70
4.9.3	Education of B Cells in the Bone Marrow and Central Tolerance . . . . .	72
	References. . . . .	73
<b>5</b>	<b>Adaptive Immunity: Effector Functions, Regulation, and Vaccination . . . . .</b>	<b>75</b>
	Paula B. Kavathas, Peter J. Krause, and Nancy H. Ruddle	
5.1	Introduction . . . . .	75
5.2	T Cell Activation . . . . .	76
5.2.1	Activation by Antigen-Presenting Cells. . . . .	76
5.2.2	Activation by Superantigens . . . . .	78
5.3	T Cell Effector Functions. . . . .	78
5.3.1	Effector Functions of CD4 T Cells . . . . .	78
5.3.2	Effector Functions of CD8 T Cells . . . . .	80
5.4	Memory . . . . .	81
5.4.1	Introduction . . . . .	81
5.4.2	Memory T Cells . . . . .	82
5.5	B Cell Activation . . . . .	83
5.5.1	Introduction . . . . .	83
5.5.2	Isotype Switching. . . . .	85
5.5.3	Somatic Hypermutation and Affinity Maturation . . . . .	85
5.6	B Cell Effector Functions . . . . .	86
5.6.1	Agglutination . . . . .	86
5.6.2	Neutralization. . . . .	87
5.6.3	Opsonization and Phagocytosis . . . . .	87
5.6.4	Antibody-Dependent Cellular Cytotoxicity (ADCC) .	88
5.6.5	IgE and Eosinophil/Mast Cell Degranulation . . . . .	88
5.6.6	Complement Activation . . . . .	88
5.7	Antibody Persistence and B Memory Cells . . . . .	89
5.8	Regulating Immune Response . . . . .	89
5.8.1	Introduction . . . . .	89
5.8.2	Negative Feedback Regulation . . . . .	89
5.8.3	Inhibitory Receptors (IRs) . . . . .	90
5.8.4	T Cell Exhaustion (Tex Cells) . . . . .	91
5.8.5	Regulation of B Lymphocytes . . . . .	91
5.9	Vaccination. . . . .	91
5.9.1	Types of Vaccines. . . . .	92
5.9.2	Summary of Types of Vaccines . . . . .	93
5.9.3	Immunoassays to Monitor Pathogen Exposure and Vaccine Efficacy . . . . .	94
	References. . . . .	94
<b>6</b>	<b>Disorders of the Immune System . . . . .</b>	<b>97</b>
	Paula B. Kavathas, Peter J. Krause, and Nancy H. Ruddle	
6.1	Introduction . . . . .	97
6.2	Immunodeficiency . . . . .	97

6.3	Hypersensitivity and Allergy .....	99
6.4	Autoimmunity .....	103
6.4.1	Mechanisms of Peripheral Tolerance.....	103
6.4.2	Gender, Genes, and Geography .....	103
6.5	Autoinflammatory Diseases.....	104
6.5.1	Definition .....	104
6.5.2	History .....	105
6.5.3	Mechanisms and Classifications .....	105
6.5.4	Treatment .....	106
6.5.5	Further Areas of Research .....	107
	References.....	107

### **Section III IMMUNOEPIDEMIOLOGY BASICS: IMMUNOLOGY OF POPULATIONS**

<b>7</b>	<b>Immunoepidemiology of Selected Components of the Innate and Adaptive Immune Systems.....</b>	111
	Nancy H. Ruddle and Paula B. Kavathas	
7.1	Introduction .....	111
7.2	Innate Immunity: Polymorphisms of Pattern Recognition Receptors.....	112
7.3	Complement.....	113
7.4	Innate and Adaptive Immunity: Cytokines, Chemokines, and their Receptors .....	113
7.4.1	Introduction .....	113
7.4.2	Cytokine Gene Polymorphisms in Human Disease.....	113
7.5	Presentation and Recognition of Self and Foreign Antigens: MHC and KIR Polymorphisms.....	114
7.5.1	MHC .....	114
7.5.2	NK Cell KIR Polymorphisms .....	116
7.6	T Cell Receptor Polymorphisms .....	118
7.7	Immunoglobulin Polymorphisms.....	121
	References.....	123
<b>8</b>	<b>Immunoepidemiology of Immune Dysfunction .....</b>	127
	Eric Meffre, Peter J. Krause, and Nancy H. Ruddle	
8.1	Introduction .....	127
8.2	Lessons from Patients with Primary Immunodeficiencies Resulting from Specific Gene Mutations.....	128
8.2.1	Definition of Primary Immunodeficiencies .....	128
8.2.2	Novel Concepts in Primary Immunodeficiencies.....	128
8.2.3	Gene Mutations Affecting Early Lymphoid Development and Severe Combined Immunodeficiency Diseases (SCID) .....	129
8.2.4	Mutations Affecting T Cell Selection and Function ..	130
8.2.5	Gene Mutations Specifically Affecting Antibody Production .....	131
8.2.6	Lymphoproliferative Syndromes .....	133

---

8.2.7	Treatment Strategies for Patients with Primary Immunodeficiencies . . . . .	134
8.3	Allergy . . . . .	135
8.3.1	Introduction . . . . .	135
8.3.2	Food Allergy Classification . . . . .	135
8.3.3	Epidemiology and Immunoepidemiology of Food Allergies . . . . .	136
8.3.4	Clinical Manifestations of Food Allergies . . . . .	137
8.3.5	Mechanism of IgE-Induced Food Allergy Symptoms . . . . .	137
8.3.6	Example of an IgE-Mediated Food Allergy: The Alpha Gal Story . . . . .	138
8.3.7	Diagnosis, Treatment, and Prevention . . . . .	138
8.4	Autoimmunity . . . . .	139
8.4.1	Introduction . . . . .	139
8.4.2	Genes . . . . .	139
8.4.3	Gender . . . . .	141
8.4.4	Geography . . . . .	143
8.4.5	Lifestyle Factors . . . . .	145
	References . . . . .	145

## Section IV IMMUNOEPIDEMIOLOGY OF INFECTIOUS DISEASES AND CANCER

9	Immunoepidemiology of <i>Mycobacterium tuberculosis</i> . . . . .	151
	Camila D. Odio and Richard J. Bucala	
9.1	<i>Mycobacterium tuberculosis</i> (MTB): Disease Burden and Presentation . . . . .	151
9.1.1	MTB Epidemiology . . . . .	151
9.1.2	MTB and the Human Immune System . . . . .	151
9.2	Impact of Other Pathogens on the Host Response to MTB . . . . .	152
9.2.1	Malaria, MTB, and Human Immunology . . . . .	152
9.2.2	HIV May Alter the Role of MIF in MTB . . . . .	153
9.3	Environmental Determinants of Host Response . . . . .	155
9.3.1	Nutrition and MTB Susceptibility . . . . .	155
9.3.2	Vitamin D and Host Defense . . . . .	155
9.4	Inherited Determinants of Host Response . . . . .	156
9.4.1	Human Leukocyte Antigen (HLA) and MTB . . . . .	156
9.5	SNP Polymorphisms and the Immune Response . . . . .	157
9.5.1	Single-Nucleotide Polymorphisms (SNPs) Overview . . . . .	157
9.5.2	Toll-like Receptors (TLRs) and MTB . . . . .	157
9.5.3	Tumor Necrosis Factor (TNF) and MTB . . . . .	158
9.6	Determinants of Extrapulmonary MTB . . . . .	159
9.6.1	IL-12-IFN- $\gamma$ Pathway and Extrapulmonary MTB . . . . .	159
9.6.2	Other SNPs Associated with Severe MTB . . . . .	160
9.7	Conclusions . . . . .	160
	References Cited . . . . .	161

<b>10 Immunoepidemiology of Human Immunodeficiency . . . . .</b>	165
Elijah Paintsil	
10.1 The Origin of the Acquired Immunodeficiency Syndrome Pandemic . . . . .	165
10.1.1 Introduction to HIV/AIDS . . . . .	165
10.1.2 The Origin of AIDS: Cross-Species Transmission of Simian Immunodeficiency Virus . . . . .	165
10.1.3 Molecular Adaptations for Successful Cross-Species Transmission of SIV . . . . .	168
10.2 Host Immune Restriction of HIV-1 Acquisition and Transmission . . . . .	169
10.2.1 Variable Host Susceptibility . . . . .	169
10.2.2 Mother-to-Child Transmission of HIV . . . . .	171
10.3 Immunoepidemiology of HIV-1 Disease Progression . . . . .	172
10.4 Lessons from HIV-1 Immunoepidemiology Leading to Therapeutic Cure and Preventative HIV-1 Vaccines . . . . .	174
10.5 Conclusions . . . . .	176
References . . . . .	176
<b>11 Fungal Immunoepidemiology . . . . .</b>	179
Marwan M. Azar	
11.1 Introduction . . . . .	179
11.2 Fungal Classification and Morphology . . . . .	180
11.3 The Innate Immune Response to Fungi . . . . .	180
11.3.1 Fungal Recognition by Antigen-Presenting Cells . . . . .	180
11.3.2 Fungal Killing by Innate Immune Cells . . . . .	181
11.4 The Adaptive Immune Response to Fungi . . . . .	184
11.4.1 T-Cell Response: Proinflammatory Responses . . . . .	184
11.4.2 T-Cell Response: Regulatory Responses . . . . .	185
11.4.3 B-Cell Response . . . . .	185
11.5 Immunoepidemiology of Fungal Infections . . . . .	186
11.5.1 Introduction . . . . .	186
11.5.2 Susceptibility to Fungal Infections in the Context of Immunodeficiencies . . . . .	186
11.5.3 Chronic Mucocutaneous Candidiasis . . . . .	186
11.5.4 Chronic Granulomatous Disease . . . . .	187
11.5.5 Acquired Immunodeficiency Syndrome with HIV Infection . . . . .	187
11.6 Susceptibility to Fungal Infections in the Context of Immunocompetent Populations . . . . .	188
11.7 Immunoepidemiologic Tools for Characterization of Fungal Geographic Distribution . . . . .	188
11.8 Vaccines Against Fungi . . . . .	189
11.9 Conclusion . . . . .	190
References . . . . .	190

---

<b>12</b>	<b>Immunoepidemiology of <i>Plasmodium falciparum</i> malaria . . . . .</b>	193
	Amy K. Bei and Sunil Parikh	
12.1	Malaria Introduction . . . . .	193
12.1.1	Global Burden of Malaria Disease . . . . .	193
12.1.2	Pathogenesis of Malaria in Humans . . . . .	193
12.1.3	Host Immune Response to Malaria . . . . .	195
12.2	Immunoepidemiology of Malaria . . . . .	197
12.2.1	Classic Cohort Studies on Immunity and Parasite Prevalence as Transmission Intensity Changes . . . . .	197
12.2.2	Serological Correlates of Protection . . . . .	198
12.2.3	Immunoepidemiology to Inform Vaccine Candidates	203
12.2.4	Serological Correlates of Exposure to Malaria . . . . .	204
12.2.5	Between-Host and Within-Host Immunological Diversity: A Systems Biology Approach . . . . .	206
12.2.6	Within-Host Immunological Diversity: The Next Frontier of Malaria Immunoepidemiology . . . . .	207
12.3	Key Challenges and Future Directions . . . . .	208
	References . . . . .	210
<b>13</b>	<b>Immunoepidemiology of Cancer . . . . .</b>	215
	Xiaomei Ma and Rong Wang	
13.1	The Role of Immune System in Cancer Prevention and Treatment . . . . .	215
13.2	Childhood Acute Lymphoblastic Leukemia . . . . .	216
13.2.1	Daycare Attendance . . . . .	217
13.2.2	Mode of Delivery . . . . .	219
13.2.3	Cytomegalovirus Infection . . . . .	220
13.2.4	Immunotherapy for Childhood ALL . . . . .	220
13.3	Glioma . . . . .	221
13.3.1	Epidemiology of Glioma . . . . .	221
13.3.2	Immunotherapy of Glioma . . . . .	222
13.4	Concluding Remarks . . . . .	223
	References . . . . .	223
<b>Section V IMMUNOEPIDEMIOLOGIC INVESTIGATIVE, THERAPEUTIC, AND PREVENTATIVE TOOLS</b>		
<b>14</b>	<b>Modeling Approaches Toward Understanding Infectious Disease Transmission . . . . .</b>	227
	Laura A. Skrip and Jeffrey P. Townsend	
14.1	Introduction . . . . .	227
14.2	Biological Aspects of Disease Transmission . . . . .	227
14.2.1	Mode of Transmission . . . . .	228
14.2.2	Course of Infection and Infectiousness . . . . .	228
14.3	Behavior and Disease Transmission . . . . .	228
14.3.1	Willingness to Accept Interventions . . . . .	228
14.3.2	Public Health Policy and Disease Awareness . . . . .	229

14.4	Infectious Disease Model Frameworks . . . . .	229
14.4.1	Model Structures . . . . .	230
14.4.2	Modeling Assumptions and Approaches . . . . .	234
14.4.3	Model Outputs: Measure of Disease Transmission. . . . .	236
14.4.4	Data-Driven Model Parameterization. . . . .	237
14.4.5	Transdisciplinary Nature of Infectious Disease Modeling . . . . .	239
14.5	The Future of Infectious Disease Epidemiology . . . . .	241
	References. . . . .	241
<b>15</b>	<b>Vaccines . . . . .</b>	<b>245</b>
	Diane McMahon-Pratt	
15.1	Introduction: Brief History of Vaccination . . . . .	245
15.2	Current Vaccines . . . . .	246
15.3	Adjuvants . . . . .	249
15.3.1	Mechanisms of Adjuvant Action . . . . .	249
15.3.2	Adjuvants: Future . . . . .	252
15.4	Vaccine Delivery Systems . . . . .	252
15.4.1	Biologic Nanoparticles . . . . .	253
15.4.2	Polymeric Nanoparticles . . . . .	254
15.5	Immunologic and Epidemiologic Challenges for Vaccines: Targets for Innovation . . . . .	255
15.5.1	Genetic Variability of Target Pathogens . . . . .	255
15.5.2	Improving Current Vaccines . . . . .	257
15.6	Population Genetic Variability and Vaccine Responses . . . . .	258
15.7	Vaccines: The Future . . . . .	259
15.7.1	Systems Biology . . . . .	259
15.7.2	Adjuvants and Delivery Systems . . . . .	260
15.7.3	Environmental Factors Impacting Vaccine Effectiveness . . . . .	260
15.7.4	Nonspecific Unintended Vaccine Effects . . . . .	261
15.7.5	Tissue Site-Specific Immunity and Memory . . . . .	261
15.7.6	Vaccine Hesitancy . . . . .	262
	References. . . . .	262
<b>16</b>	<b>Immunotherapy for Infectious Diseases, Cancer, and Autoimmunity . . . . .</b>	<b>265</b>
	Peter J. Krause, Paula B. Kavathas, and Nancy H. Ruddle	
16.1	Introduction . . . . .	265
16.2	Immunotherapy for Infectious Diseases . . . . .	265
16.2.1	Introduction . . . . .	265
16.2.2	Production of Monoclonal Antibodies . . . . .	266
16.2.3	Examples of Antibody Treatment of Infectious Diseases . . . . .	268
16.3	Immunotherapy for Cancer . . . . .	268
16.4	Immunotherapy for Autoimmunity . . . . .	271
16.4.1	Introduction . . . . .	271
16.4.2	Cytokine Therapies . . . . .	272

16.4.3	Anti-cytokine Therapies . . . . .	272
16.4.4	Cell-Directed Immunotherapies . . . . .	274
16.4.5	Additional Therapies . . . . .	275
16.5	Conclusions . . . . .	275
	References . . . . .	275
	<b>Appendix</b> . . . . .	277
	<b>Bibliography</b> . . . . .	283
	<b>Index</b> . . . . .	289

---

## Contributors

**Marwan M. Azar** Department of Medicine (Infectious Diseases), Yale University School of Medicine, New Haven, CT, USA

**Amy K. Bei** Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA

**Richard J. Bucala** Departments of Medicine (Rheumatology), Pathology, and Epidemiology, Yale School of Medicine, New Haven, CT, USA

**Kara Fikrig** Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA

**Paula B. Kavathas** Departments of Laboratory Medicine and Immunobiology, Yale School of Medicine, New Haven, CT, USA

**Peter J. Krause** Department of Epidemiology of Microbial Diseases, Yale School of Public Health and Departments of Medicine and Pediatrics, Yale School of Medicine, New Haven, CT, USA

**Xiaomei Ma** Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA

**Diane McMahon-Pratt** Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA

**Eric Meffre** Departments of Immunobiology and Internal Medicine, Yale University School of Medicine, New Haven, CT, USA

**Linda M. Niccolai** Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA

**Kate Nyhan** Harvey Cushing/John Hay Whitney Medical Library, Yale University, New Haven, CT, USA

**Jane O'Bryan** Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA

**Camila D. Odio** Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA

**Elijah Paintsil** Departments of Pediatrics, Pharmacology, and Epidemiology of Microbial Diseases, Yale School of Medicine and Yale School of Public Health, New Haven, CT, USA

**Sunil Parikh** Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA

**Nancy H. Ruddle** Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA

**Laura A. Skrip** Department of Epidemiology of Microbial Disease, Yale School of Public Health, New Haven, CT, USA

**Jeffrey P. Townsend** Department of Biostatistics, Yale School of Public Health, Yale University, New Haven, CT, USA

**Rong Wang** Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA

---

## Abbreviations

$\beta_2$ M	$\beta_2$ -Microglobulin
ABPA	Allergic bronchopulmonary aspergillosis
ADA	Adenosine deaminase
ADCC	Antibody-dependent cellular cytotoxicity
ADCI	Antibody-mediated cellular inhibition
ADRB	Antibody-dependent respiratory burst
AIDS	Acquired immunodeficiency syndrome
AIRE	Autoimmune regulator
ALL	Acute lymphoblastic leukemia
ALPS	Autoimmune lymphoproliferative syndrome
Als3p	Agglutinin-like sequence 3 protein
Alum	KAl(SO <sub>4</sub> ) <sub>2</sub> ·12H <sub>2</sub> O
AMA-1	Apical membrane antigen-1
AMD	Adult onset macular degeneration
AML	Acute myeloid leukemia
APC	Antigen-presenting cell
APCED	Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy
APO BEC3	Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3
APS-1	Autoimmune polyendocrine syndrome type 1
ART	Antiretroviral therapy
ASC	Apoptosis-associated speck-like protein containing CARD
BALT	Bronchial-associated lymphoid tissue
BCG	Bacillus Calmette-Guérin
BCR	B-cell receptor
BMI	Body mass index
BTK	Bruton tyrosine kinase
CAR	Chimeric antigen receptor
CCL	CC ligand
CCR5	C-C motif receptor 5 gene
CCR5Δ32	A 32-base pair deletion within the coding region of CCR5
CD	Cluster of differentiation
CD	Crohn's disease
cDC	Conventional dendritic cell
CDC	US Center for Disease Control and Prevention
CDR	Complementarity determining region

CGA	Candidate gene analysis
cGAMP	Cyclic GMP-AMP
CGD	Chronic granulomatous disease
CHMI	Controlled human malaria infection
CLP	Common lymphoid progenitor
CLR	C-type lectin receptor
CMC	Chronic mucocutaneous candidiasis
CMP	Common myeloid precursor
CMV	Cytomegalovirus
CoP	Correlate of protection
CpG	Cytosine phosphate guanine dinucleotide
CSA	Chondroitinsulfate A
C-section	Cesarean section
CSP	Circumsporozoite protein
CSR	Class switch recombination
cTEC	Cortical thymic epithelial cell
CTL	Cytotoxic T-lymphocyte
CTLA-4	Cytotoxic T-lymphocyte-associated protein 4
CVID	Common variable immunodeficiency disease
CXCL	CXC ligand
DAMP	Danger-associated molecular pattern
DC	Dendritic cell
DMARDs	Disease modifying antirheumatic drugs
dMN	Dissolvable microneedles
EBV	Epstein-Barr virus
ER	Endoplasmic reticulum
ERAP1	Endoplasmic reticulum aminopeptidase 1
ERBB2	Human epidermal growth factor receptor 2
ESN	Exposed seronegative
Fab	Fragment antigen-binding
Fc	Fragment crystallizable
FDA	Food and Drug Administration
FDC	Follicular dendritic cell
FDEIA	Food-dependent exercise-induced allergy
FHF	Familial Hibernian fever
FKS	Formalin-killed spherule
FMF	Familial Mediterranean fever
G6PD	Glucose-6-phosphate dehydrogenase
GAFFI	Global Action Fund for Fungal Infections
GALT	Gut-associated lymphoid tissue
GAP	Genetically attenuated parasite
GC	Germinal center
GI	Gastrointestinal tract
GIA	Growth inhibition assay
GLA	Glucopyranosyl lipid A
GM-CSF	Granulocyte monocyte colony stimulating factor
GWAS	Genome-wide association study
HAART	Highly active antiretroviral therapy